{
  "abstract": "Tyrosine kinase inhibitor (TKI) therapy has resulted in a significant reduction in chronic myeloid leukemia (CML)-related mortality. However, the impact of TKIs on the health status of long-term CML survivors remains unstudied. We examined the health status of 62 TKI-treated CML patients who did not receive blood or marrow transplantation (BMT) (CML_TKI; median follow-up: 12.5 y) compared with an unaffected population (303 non-CML controls), and CML patients treated with BMT but without TKI exposure (220 CML_BMT; median follow-up 19.4 y). Participants self-reported general health, functional status, activity limitations, and pre-frailty/frailty. Overall, 71.0% of CML_TKI participants had ≥1 adversely-affected domain vs. 42.6% of non-CML and 65.9% of CML_BMT participants. When compared with the non-CML controls, the CML_TKI cohort was more like to have poor general health (aOR = 4.43, 95%CI = 1.8–10.7), functional impairment (aOR=2.84, 95%CI = 1.4–6.0), and activity limitation (aOR=3.37, 95%CI = 1.7–6.7) and more likely to be frail/pre-frail (aOR=3.71, 95%CI = 1.7–8.1). The CML_TKI and CML_BMT cohorts were comparable with respect to poor general health (aOR = 0.95, 95%CI = 0.5–2.0), functional impairment (aOR = 1.59, 95%CI = 0.8–3.0), and pre-frailty/frailty (aOR = 1.92, 95%CI = 0.92–4.0), but the CML_TKI cohort was more likely to report activity limitation (aOR = 2.2, 95%CI = 1.1–4.5). These findings inform a need for long-term monitoring and development of risk mitigation strategies to improve the health status as a treatment goal in CML care.",
  "abstract_shown": true,
  "affiliations": [
    "University of Alabama at Birmingham, Birmingham, AL USA",
    "City of Hope, Duarte, CA USA",
    "University of Minnesota, Minneapolis, MN USA"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 16,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Smita Bhatia",
      "orcid": "0000-0002-7755-5683"
    },
    {
      "affs": [
        0
      ],
      "name": "Qingrui Meng"
    },
    {
      "affs": [
        0
      ],
      "name": "Lindsey Hageman"
    },
    {
      "affs": [
        0
      ],
      "name": "Sarah B. Palmer"
    },
    {
      "affs": [
        0
      ],
      "name": "Eunice E. Choe"
    },
    {
      "affs": [
        0
      ],
      "name": "Nora Balas"
    },
    {
      "affs": [
        0
      ],
      "name": "Wendy Landier",
      "orcid": "0000-0003-3319-5652"
    },
    {
      "affs": [
        0
      ],
      "name": "Omer Jamy",
      "orcid": "0000-0003-2411-4742"
    },
    {
      "affs": [
        0
      ],
      "name": "Pankit Vachhani",
      "orcid": "0000-0001-9779-6217"
    },
    {
      "affs": [
        1
      ],
      "name": "Alysia Bosworth",
      "orcid": "0000-0002-0662-5699"
    },
    {
      "affs": [
        1
      ],
      "name": "F. Lennie Wong"
    },
    {
      "affs": [
        0
      ],
      "name": "Jorge Cortes"
    },
    {
      "affs": [
        1
      ],
      "name": "Stephen J. Forman",
      "orcid": "0000-0002-2803-4152"
    },
    {
      "affs": [
        2
      ],
      "name": "Daniel J. Weisdorf",
      "orcid": "0000-0001-8078-8579"
    },
    {
      "affs": [
        1
      ],
      "name": "Saro H. Armenian"
    },
    {
      "affs": [
        0
      ],
      "name": "Ravi Bhatia",
      "orcid": "0000-0001-5740-2316"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/0mcha8a2ttc4t.bib",
  "cited_by": 0,
  "doi": "10.1038/s41375-026-03123-w",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13713547/",
  "id": "0mcha8a2ttc4t",
  "issns": [
    "0887-6924",
    "1476-5551"
  ],
  "landing_url": "https://doi.org/10.1038/s41375-026-03123-w",
  "language": "en",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Article"
    ],
    [
      "openalex",
      "2720|Chronic Myeloid Leukemia Treatments"
    ]
  ],
  "openalex": "W7203919904",
  "pdf_url": "https://www.nature.com/articles/s41375-026-03123-w.pdf",
  "pmcid": "PMC13713547",
  "pmid": "42629391",
  "published": "2026-08-21",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/0mcha8a2ttc4t.ris",
  "sources": [
    {
      "first_seen": "2026-10-31T12:24:04Z",
      "native_id": "PMC13713547",
      "source": "pmc",
      "url": "https://doi.org/10.1038/s41375-026-03123-w"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2720|Chronic Myeloid Leukemia Treatments",
      "subfield": "general"
    }
  ],
  "title": "Health status impairments in tyrosine kinase inhibitor-treated chronic myeloid leukemia patients versus blood or marrow transplant survivors and non-cancer controls",
  "title_text": "Health status impairments in tyrosine kinase inhibitor-treated chronic myeloid leukemia patients versus blood or marrow transplant survivors and non-cancer controls",
  "type": "peer-reviewed",
  "updated_at": "2026-11-01T12:21:12Z",
  "url": "https://research.draconitic.com/paper/0mcha8a2ttc4t",
  "venue": "Leukemia",
  "versions": []
}